Shawn K. Singh, J.D.

Shawn K. Singh, J.D.

President, Chief Executive Officer and DirectoratVistagen Therapeutics· In proxies 2022–2025

Pay in FY2025+161% from the year before · Vistagen Therapeutics stock -52.7% the same year

Shawn K. Singh, J.D. was paid $2.5M in FY2025 (Mar), up 161%. Vistagen Therapeutics stock fell 52.7% that year.

Pay$100 in the stock at the end of FY21 → $4
Pay is from the Summary Compensation Table of each Vistagen Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Vistagen TherapeuticsPublic company · 4 yr
    • President, Chief Executive Officer and Director2022 – Present · 4 yrStock in role -100%
  2. Annual MeetingPublic company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?